Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.000.81%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -44.99% | 23.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -44.99% | 23.49% | |||
| Operating Income | 44.99% | -23.49% | |||
| Income Before Tax | 54.80% | -70.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 54.80% | -70.18% | |||
| Earnings from Discontinued Operations | -- | 804.77% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -116.98% | 340.39% | |||
| EBIT | 44.99% | -23.49% | |||
| EBITDA | 74.12% | -45.64% | |||
| EPS Basic | 97.88% | 86.23% | |||
| Normalized Basic EPS | 72.36% | 92.38% | |||
| EPS Diluted | 97.88% | 86.23% | |||
| Normalized Diluted EPS | 72.36% | 92.38% | |||
| Average Basic Shares Outstanding | 63.12% | 2,131.24% | |||
| Average Diluted Shares Outstanding | 63.12% | 2,131.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||